Feedback / Questions
FYB201 (ranibizumab biosimilar) - Amneal, Formycon, Coherus Biosci, Teva
https://www.globenewswire.com/news-release/2021/10/01/2307290/0/en/Coherus-Announces-BLA-Filing-for-Lucentis-ranibizumab-Biosimilar-Candidate-Accepted-by-FDA-for-Review.html
Oct 1, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next